FORIGERIMOD ACETATE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22356680 | https://clinicaltrials.gov/ct2/show/NCT03427151

Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.

Approval Year

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

200 mcg of IPP-201101 (FORIGERIMOD) will be administered subcutaneously every 4 weeks for 24 weeks.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Sat Dec 16 01:47:34 GMT 2023` Edited by `admin` on `Sat Dec 16 01:47:34 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	YU54FAR97X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FORIGERIMOD ACETATE

Official Name

English

P-140

Code

English

LUPUZOR

Brand Name

English

CEP-33457

Code

English

Forigerimod acetate [WHO-DD]

Common Name

English

FORIGERIMOD ACETATE [USAN]

Common Name

English

L-TYROSINE, L-ARGINYL-L-ISOLEUCYL-L-HISTIDYL-L-METHIONYL-L-VALYL-L-TYROSYL-L-SERYL-L-LYSYL-L-ARGINYL-O-PHOSPHONO-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-ARGINYLGLYCYL-L-TYROSYL-L-ALANYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-, ACETATE

Common Name

English

P140

Code

English

Code System Code Type Description

NCI_THESAURUS

C170004